BEAUTY HEALTH Reports 9.7% YOY Revenue Increase in Third Quarter of FY2023, Totaling USD 97.4 Million
November 21, 2023
☀️Earnings Overview
For the third quarter of FY2023, BEAUTY HEALTH ($NASDAQ:SKIN) reported a total revenue of USD 97.4 million, indicating a 9.7% year-on-year growth. Despite this, its net income was USD -73.8 million, an immense decrease from the 0.1 million reported in the same quarter of the prior year.
Analysis
GoodWhale has conducted a thorough analysis of BEAUTY HEALTH‘s fundamentals. According to the Star Chart, BEAUTY HEALTH is strong in growth, medium in asset, profitability and weak in dividend. This has classified BEAUTY HEALTH as a ‘cheetah’, meaning that it is more focused on achieving high revenue or earnings growth. This type of company is considered to be less stable due to lower profitability. This type of company may be of interest to investors who are looking for high growth potential but are willing to accept a higher degree of risk. In terms of health, BEAUTY HEALTH has an intermediate score of 4/10 with regards to its cashflows and debt, suggesting that it is likely to sustain future operations in times of crisis. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Beauty Health. More…
| Total Revenues | Net Income | Net Margin |
| 399.3 | -84.02 | -24.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Beauty Health. More…
| Operations | Investing | Financing |
| 21.53 | -32.16 | -108.57 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Beauty Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 973.07 | 883.12 | 0.68 |
Key Ratios Snapshot
Some of the financial key ratios for Beauty Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 30.0% | – | -18.5% |
| FCF Margin | ROE | ROA |
| 2.0% | -36.7% | -4.7% |
Peers
The company’s products are available in more than 30 countries and it has a strong presence in the United States, Europe, and Asia. The company’s products are sold through a network of distributors, retailers, and online retailers. The company has a strong focus on research and development and has a team of scientists that are constantly innovating new products. The company’s products are backed by a 100% satisfaction guarantee.
– Hims & Hers Health Inc ($NYSE:HIMS)
Hims & Hers Health Inc. is a digital healthcare company that offers direct-to-consumer telehealth and online pharmacy services. The company was founded in 2017 and is headquartered in San Francisco, California. As of 2022, the company had a market cap of 880.33M and a ROE of -15.86%. The company offers a range of services including primary care, sexual health, mental health, and more.
– Yoshitsu Co Ltd ($NASDAQ:TKLF)
The company has a market cap of 47.13M as of 2022. The company’s ROE for the same period is 14.38%. The company is engaged in the business of manufacturing textile products.
– CI Medical Co Ltd ($TSE:3540)
Founded in 1971, CIC Medical is a leading provider of medical devices and services. The company’s products are used in a variety of medical applications, including surgery, diagnostics, and patient care. CIC Medical has a market cap of 51.4 billion as of 2022 and a return on equity of 15.93%. The company’s products are used in a variety of medical applications, including surgery, diagnostics, and patient care.
Summary
BEAUTY HEALTH reported a 9.7% increase in its total revenue for the third quarter of FY2023, compared to the previous year. However, the company experienced a net loss of -73.8 million, compared to a net income of 0.1 million for the same quarter in the previous year. Despite this, the stock price moved up in response. Investors should pay close attention to BEAUTY HEALTH’s financial performance before deciding whether to invest, as it is necessary to ensure the company is able to generate sufficient profits in order to be a viable investment option.
Related Posts
Recent Posts
